Skip to content
Screener

Other segment segments

Latin America
$600K+20.0%
North America
$400K0.0%
JPAC
$300K-25.0%
EMEA
$100K-85.7%

Similar metrics at other companies

Veradermics logo
MANER&D
$20.93M+82.8%
Polaryx Therapeutics, Inc. logo
PLYXR&D
$679K-85.6%
Schering-Plough logo
SGPR&D
$8.54M+41.1%
Deere & Company logo
DER&D
$583M+6.2%
Roblox logo
RBLXR&D
$422M+12.8%
Salesforce logo
CRMR&D
$1.63B+11.4%

Other financials

Income statement

See full
Revenue$630.9M+2.8%
Gross profit$272.9M-0.7%
Operating income-$21.8M+87.9%
Net income-$92.9M+63.6%
EPS (diluted)-$1.36+63.9%

Balance sheet

See full
Cash & equivalents$123.4M-18.7%
Total debt$3.4B+3.0%
Total equity$1.8B-36.4%
Total assets$5.7B-10.4%

Cash flow

See full
Operating cash flow-$110.6M
CapEx$25.5M-32.0%
Free cash flow-$136.1M-61.4%

Valuation

See full
Market cap$837.73M-47.8%
Enterprise value$4.15B-13.4%
P/S0.3×-0.3×

Profitability

See full
Gross margin44.6%-2.7pp
Operating margin-30.8%-49.9pp
Net margin-39.2%-168pp
FCF margin13.8%

Returns & leverage

See full
Return on equity-45.9%-94.9pp
Debt / equity1.9×+0.7×
Current ratio1.4×+0.3×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept qdel:SegmentInformationResearchAndDevelopmentExpense.

The source filing: QuidelOrtho Corporation’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0001906324-26-000033
(In millions)North AmericaEMEAChinaJPACLatin AmericaTotal
Less (1):
Cost of sales, excluding amortization of intangibles116.744.328.843.338.3271.4
Selling, marketing and administrative40.723.99.512.313.299.6
Research and development0.40.10.60.30.62.0
Other expense, net0.8(1.4)0.1(1.6)(2.1)
Total segment Adjusted EBITDA$169.6$22.1$30.3$18.3$19.7260.0
Reconciliation of segment Adjusted EBITDA
Corporate (2)(130.7)

Item 1. Financial Statements (unaudited)

FAQ

What is QuidelOrtho Corporation's china — R&D?
QuidelOrtho Corporation (QDEL) reported china — R&D of $600K in Q2 2026.
How has QuidelOrtho Corporation's china — R&D changed year-over-year?
QuidelOrtho Corporation's china — R&D decreased by 25.0% year-over-year, from $800K to $600K.
What is the long-term trend for QuidelOrtho Corporation's china — R&D?
Over 3 years (2022 to 2025), QuidelOrtho Corporation's china — R&D has grown at a 8.9% compound annual growth rate (CAGR), from $2.4M to $3.1M.
What does china — R&D mean?
Reflects the capital and operational resources allocated to research and development activities specifically tailored for the China market. It indicates the company's commitment to local innovation and adapting diagnostic technologies to meet regional clinical requirements.

Ask your AI about QuidelOrtho Corporation's china — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude